{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,12]],"date-time":"2026-03-12T04:37:07Z","timestamp":1773290227991,"version":"3.50.1"},"reference-count":42,"publisher":"American Association for Cancer Research (AACR)","issue":"9","content-domain":{"domain":["aacrjournals.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2007,5,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:p>Purpose: Epidermal growth factor (EGF) plays a critical role in cancer. A polymorphism in the EGF gene (EGF+61) may influence its expression and contribute to cancer predisposition and aggressiveness. In the present study, we aimed to elucidate the role of EGF+61 in glioma susceptibility and prognosis.<\/jats:p>\n               <jats:p>Experimental Design: A case-control study involving 197 glioma patients and 570 controls was done. Univariate and multivariate logistic regression analyses were used to calculate odds ratio (OR) and 95% confidence intervals (95% CI). False-positive report probability was also assessed. The luciferase reporter gene assay was used to ascertain the functional consequences of this polymorphism.<\/jats:p>\n               <jats:p>Results: Corroborating the univariate analysis, the multivariate model showed that the G allele conferred higher risks for gliomas (OR, 1.32; 95% CI, 1.04-1.67), glioblastomas (OR, 1.47; 95% CI, 1.02-2.10), and oligodendrogliomas (OR, 1.55; 95% CI, 1.07-2.23). The GG genotypes were associated with increased risk for gliomas (OR, 1.71; 95% CI, 1.07-2.73), glioblastomas (OR, 2.03; 95% CI, 1.02-4.05), and oligodendrogliomas (OR, 2.72; 95% CI, 1.18-6.28). In addition, the AG+GG genotypes were associated with higher risk for gliomas (OR, 1.52; 95% CI, 1.03-2.23) and oligodendrogliomas (OR, 2.80; 95% CI, 1.35-5.79). No significant association was observed between the EGF+61 polymorphism and glioblastoma or oligodendroglioma patients' overall survival. The luciferase reporter gene assay exhibited a significant increased promoter activity for the G variant compared with the reference A allele.<\/jats:p>\n               <jats:p>Conclusions: These findings support the role of the EGF+61 polymorphism as a susceptibility factor for development of gliomas and show its implication on EGF promoter activity.<\/jats:p>","DOI":"10.1158\/1078-0432.ccr-06-2606","type":"journal-article","created":{"date-parts":[[2007,5,1]],"date-time":"2007-05-01T18:31:55Z","timestamp":1178044315000},"page":"2621-2626","update-policy":"https:\/\/doi.org\/10.1158\/crossmark_policy","source":"Crossref","is-referenced-by-count":70,"title":["Association between Functional <i>EGF<\/i>+61 Polymorphism and Glioma Risk"],"prefix":"10.1158","volume":"13","author":[{"given":"Bruno Marques","family":"Costa","sequence":"first","affiliation":[{"name":"1Life and Health Sciences Research Institute (ICVS), School of Health Sciences and"}]},{"given":"Paulo","family":"Ferreira","sequence":"additional","affiliation":[{"name":"4IPATIMUP\u2014Institute of Molecular Pathology and Immunology; and"}]},{"given":"Sandra","family":"Costa","sequence":"additional","affiliation":[{"name":"1Life and Health Sciences Research Institute (ICVS), School of Health Sciences and"}]},{"given":"Paulo","family":"Canedo","sequence":"additional","affiliation":[{"name":"4IPATIMUP\u2014Institute of Molecular Pathology and Immunology; and"}]},{"given":"Pedro","family":"Oliveira","sequence":"additional","affiliation":[{"name":"2Department of Production and Systems Engineering, University of Minho;"}]},{"given":"Ana","family":"Silva","sequence":"additional","affiliation":[{"name":"3Department of Pathology, Hospital S. Marcos, Braga, Portugal;"}]},{"given":"Fernando","family":"Pardal","sequence":"additional","affiliation":[{"name":"3Department of Pathology, Hospital S. Marcos, Braga, Portugal;"}]},{"given":"Gianpaolo","family":"Suriano","sequence":"additional","affiliation":[{"name":"4IPATIMUP\u2014Institute of Molecular Pathology and Immunology; and"}]},{"given":"Jose\u0301 Carlos","family":"Machado","sequence":"additional","affiliation":[{"name":"4IPATIMUP\u2014Institute of Molecular Pathology and Immunology; and"},{"name":"5Medical Faculty, Department of Pathology, Hospital S. Joa\u0303o, University of Porto, Porto, Portugal"}]},{"given":"Jose\u0301 Manuel","family":"Lopes","sequence":"additional","affiliation":[{"name":"4IPATIMUP\u2014Institute of Molecular Pathology and Immunology; and"},{"name":"5Medical Faculty, Department of Pathology, Hospital S. Joa\u0303o, University of Porto, Porto, Portugal"}]},{"given":"Rui Manuel","family":"Reis","sequence":"additional","affiliation":[{"name":"1Life and Health Sciences Research Institute (ICVS), School of Health Sciences and"}]}],"member":"1086","published-online":{"date-parts":[[2007,5,1]]},"reference":[{"key":"2022061105411834700_B1","doi-asserted-by":"crossref","unstructured":"Jemal A, Murray T, Ward E, et al. Cancer statistics, 2005. CA Cancer J Clin\u20082005;55:10\u201330.","DOI":"10.3322\/canjclin.55.1.10"},{"key":"2022061105411834700_B2","doi-asserted-by":"crossref","unstructured":"Burnet NG, Jefferies SJ, Benson RJ, Hunt DP, Treasure FP. Years of life lost (YLL) from cancer is an important measure of population burden\u2014and should be considered when allocating research funds. Br J Cancer\u20082005;92:241\u20135.","DOI":"10.1038\/sj.bjc.6602321"},{"key":"2022061105411834700_B3","unstructured":"Kleihues P, Cavanee WK. Pathology and genetics of tumours of the nervous system. 2nd ed. Lyon: IARC Press; 2000."},{"key":"2022061105411834700_B4","doi-asserted-by":"crossref","unstructured":"Butowski NA, Sneed PK, Chang SM. Diagnosis and treatment of recurrent high-grade astrocytoma. J Clin Oncol\u20082006;24:1273\u201380.","DOI":"10.1200\/JCO.2005.04.7522"},{"key":"2022061105411834700_B5","doi-asserted-by":"crossref","unstructured":"Davis FG, Freels S, Grutsch J, Barlas S, Brem S. Survival rates in patients with primary malignant brain tumors stratified by patient age and tumor histological type: an analysis based on Surveillance, Epidemiology, and End Results (SEER) data, 1973-1991. J Neurosurg\u20081998;88:1\u201310.","DOI":"10.3171\/jns.1998.88.1.0001"},{"key":"2022061105411834700_B6","doi-asserted-by":"crossref","unstructured":"Hanahan D, Weinberg RA. The hallmarks of cancer. Cell\u20082000;100:57\u201370.","DOI":"10.1016\/S0092-8674(00)81683-9"},{"key":"2022061105411834700_B7","doi-asserted-by":"crossref","unstructured":"Xian CJ, Zhou XF. EGF family of growth factors: essential roles and functional redundancy in the nerve system. Front Biosci\u20082004;9:85\u201392.","DOI":"10.2741\/1210"},{"key":"2022061105411834700_B8","doi-asserted-by":"crossref","unstructured":"Zhu Y, Parada LF. The molecular and genetic basis of neurological tumours. Nat Rev Cancer\u20082002;2:616\u201326.","DOI":"10.1038\/nrc866"},{"key":"2022061105411834700_B9","doi-asserted-by":"crossref","unstructured":"Salomon DS, Brandt R, Ciardiello F, Normanno N. Epidermal growth factor-related peptides and their receptors in human malignancies. Crit Rev Oncol Hematol\u20081995;19:183\u2013232.","DOI":"10.1016\/1040-8428(94)00144-I"},{"key":"2022061105411834700_B10","unstructured":"Ekstrand AJ, James CD, Cavenee WK, Seliger B, Pettersson RF, Collins VP. Genes for epidermal growth factor receptor, transforming growth factor \u03b1, and epidermal growth factor and their expression in human gliomas in vivo. Cancer Res\u20081991;51:2164\u201372."},{"key":"2022061105411834700_B11","doi-asserted-by":"crossref","unstructured":"Hunter KW, Crawford NP. Germ line polymorphism in metastatic progression. Cancer Res\u20082006;66:1251\u20134.","DOI":"10.1158\/0008-5472.CAN-05-3705"},{"key":"2022061105411834700_B12","doi-asserted-by":"crossref","unstructured":"Loktionov A. Common gene polymorphisms, cancer progression and prognosis. Cancer Lett\u20082004;208:1\u201333.","DOI":"10.1016\/j.canlet.2004.02.009"},{"key":"2022061105411834700_B13","doi-asserted-by":"crossref","unstructured":"Ulrich CM, Robien K, McLeod HL. Cancer pharmacogenetics: polymorphisms, pathways and beyond. Nat Rev Cancer\u20082003;3:912\u201320.","DOI":"10.1038\/nrc1233"},{"key":"2022061105411834700_B14","doi-asserted-by":"crossref","unstructured":"Nagasubramanian R, Innocenti F, Ratain MJ. Pharmacogenetics in cancer treatment. Annu Rev Med\u20082003;54:437\u201352. Epub 2001 Dec 3.","DOI":"10.1146\/annurev.med.54.101601.152352"},{"key":"2022061105411834700_B15","doi-asserted-by":"crossref","unstructured":"Zhang W, Gordon M, Press OA, et al. Cyclin D1 and epidermal growth factor polymorphisms associated with survival in patients with advanced colorectal cancer treated with Cetuximab. Pharmacogenomics\u20082006;16:475\u201383.","DOI":"10.1097\/01.fpc.0000220562.67595.a5"},{"key":"2022061105411834700_B16","doi-asserted-by":"crossref","unstructured":"Shahbazi M, Pravica V, Nasreen N, et al. Association between functional polymorphism in EGF gene and malignant melanoma. Lancet\u20082002;359:397\u2013401.","DOI":"10.1016\/S0140-6736(02)07600-6"},{"key":"2022061105411834700_B17","doi-asserted-by":"crossref","unstructured":"McCarron SL, Bateman AC, Theaker JM, Howell WM. EGF +61 gene polymorphism and susceptibility to and prognostic markers in cutaneous malignant melanoma. Int J Cancer\u20082003;107:673\u20135.","DOI":"10.1002\/ijc.11448"},{"key":"2022061105411834700_B18","doi-asserted-by":"crossref","unstructured":"Amend KL, Elder JT, Tomsho LP, et al. EGF gene polymorphism and the risk of incident primary melanoma. Cancer Res\u20082004;64:2668\u201372.","DOI":"10.1158\/0008-5472.CAN-03-3855"},{"key":"2022061105411834700_B19","doi-asserted-by":"crossref","unstructured":"Randerson-Moor JA, Gaut R, Turner F, et al. The relationship between the epidermal growth factor (EGF) 5\u2032UTR variant A61G and melanoma\/nevus susceptibility. J Invest Dermatol\u20082004;123:755\u20139.","DOI":"10.1111\/j.0022-202X.2004.23304.x"},{"key":"2022061105411834700_B20","doi-asserted-by":"crossref","unstructured":"Howell WM. Epidermal growth factor gene polymorphism and development of cutaneous melanoma. J Invest Dermatol\u20082004;123:xx\u2013xxi.","DOI":"10.1111\/j.0022-202X.2004.23308.x"},{"key":"2022061105411834700_B21","doi-asserted-by":"crossref","unstructured":"James MR, Hayward NK, Dumenil T, Montgomery GW, Martin NG, Duffy DL. Epidermal growth factor gene (EGF) polymorphism and risk of melanocytic neoplasia. J Invest Dermatol\u20082004;123:760\u20132.","DOI":"10.1111\/j.0022-202X.2004.23305.x"},{"key":"2022061105411834700_B22","doi-asserted-by":"crossref","unstructured":"Okamoto I, Roka F, Krogler J, et al. The EGF A61G polymorphism is associated with disease-free period and survival in malignant melanoma. J Invest Dermatol\u20082006;126:2242\u20136.","DOI":"10.1038\/sj.jid.5700377"},{"key":"2022061105411834700_B23","doi-asserted-by":"crossref","unstructured":"Bhowmick DA, Zhuang Z, Wait SD, Weil RJ. A functional polymorphism in the EGF gene is found with increased frequency in glioblastoma multiforme patients and is associated with more aggressive disease. Cancer Res\u20082004;64:1220\u20133.","DOI":"10.1158\/0008-5472.CAN-03-3137"},{"key":"2022061105411834700_B24","doi-asserted-by":"crossref","unstructured":"Basto D, Trovisco V, Lopes JM, et al. Mutation analysis of B-RAF gene in human gliomas. Acta Neuropathol (Berl)\u20082005;109:207\u201310.","DOI":"10.1007\/s00401-004-0936-x"},{"key":"2022061105411834700_B25","unstructured":"Mullenbach R, Lagoda PJ, Welter C. An efficient salt-chloroform extraction of DNA from blood and tissues. Trends Genet\u20081989;5:391."},{"key":"2022061105411834700_B26","doi-asserted-by":"crossref","unstructured":"Wacholder S, Chanock S, Garcia-Closas M, El GL, Rothman N. Assessing the probability that a positive report is false: an approach for molecular epidemiology studies. J Natl Cancer Inst\u20082004;96:434\u201342.","DOI":"10.1093\/jnci\/djh075"},{"key":"2022061105411834700_B27","doi-asserted-by":"crossref","unstructured":"Ohgaki H, Kleihues P. Epidemiology and etiology of gliomas. Acta Neuropathol (Berl)\u20082005;109:93\u2013108.","DOI":"10.1007\/s00401-005-0991-y"},{"key":"2022061105411834700_B28","doi-asserted-by":"crossref","unstructured":"Ron E, Modan B, Boice JD, Jr., et al. Tumors of the brain and nervous system after radiotherapy in childhood. N Engl J Med\u20081988;319:1033\u20139.","DOI":"10.1056\/NEJM198810203191601"},{"key":"2022061105411834700_B29","doi-asserted-by":"crossref","unstructured":"Neglia JP, Meadows AT, Robison LL, et al. Second neoplasms after acute lymphoblastic leukemia in childhood. N Engl J Med\u20081991;325:1330\u20136.","DOI":"10.1056\/NEJM199111073251902"},{"key":"2022061105411834700_B30","doi-asserted-by":"crossref","unstructured":"Relling MV, Rubnitz JE, Rivera GK, et al. High incidence of secondary brain tumours after radiotherapy and antimetabolites. Lancet\u20081999;354:34\u20139.","DOI":"10.1016\/S0140-6736(98)11079-6"},{"key":"2022061105411834700_B31","doi-asserted-by":"crossref","unstructured":"Walter AW, Hancock ML, Pui CH, et al. Secondary brain tumors in children treated for acute lymphoblastic leukemia at St Jude Children's Research Hospital. J Clin Oncol\u20081998;16:3761\u20137.","DOI":"10.1200\/JCO.1998.16.12.3761"},{"key":"2022061105411834700_B32","doi-asserted-by":"crossref","unstructured":"Wrensch M, Fisher JL, Schwartzbaum JA, Bondy M, Berger M, Aldape KD. The molecular epidemiology of gliomas in adults. Neurosurg Focus\u20082005;19:E5.","DOI":"10.3171\/foc.2005.19.5.6"},{"key":"2022061105411834700_B33","doi-asserted-by":"crossref","unstructured":"Wiencke JK, Aldape K, McMillan A, et al. Molecular features of adult glioma associated with patient race\/ethnicity, age, and a polymorphism in O6-methylguanine-DNA-methyltransferase. Cancer Epidemiol Biomarkers Prev\u20082005;14:1774\u201383.","DOI":"10.1158\/1055-9965.EPI-05-0089"},{"key":"2022061105411834700_B34","doi-asserted-by":"crossref","unstructured":"Wang LE, Bondy ML, Shen H, et al. Polymorphisms of DNA repair genes and risk of glioma. Cancer Res\u20082004;64:5560\u20133.","DOI":"10.1158\/0008-5472.CAN-03-2181"},{"key":"2022061105411834700_B35","unstructured":"Caggana M, Kilgallen J, Conroy JM, et al. Associations between ERCC2 polymorphisms and gliomas. Cancer Epidemiol Biomarkers Prev\u20082001;10:355\u201360."},{"key":"2022061105411834700_B36","unstructured":"Elexpuru-Camiruaga J, Buxton N, Kandula V, et al. Susceptibility to astrocytoma and meningioma: influence of allelism at glutathione S-transferase (GSTT1 and GSTM1) and cytochrome P-450 (CYP2D6) loci. Cancer Res\u20081995;55:4237\u20139."},{"key":"2022061105411834700_B37","unstructured":"Ezer R, Alonso M, Pereira E, et al. Identification of glutathione S-transferase (GST) polymorphisms in brain tumors and association with susceptibility to pediatric astrocytomas. J Neurooncol\u20082002;59:123\u201334."},{"key":"2022061105411834700_B38","doi-asserted-by":"crossref","unstructured":"Wrensch M, Kelsey KT, Liu M, et al. Glutathione-S-transferase variants and adult glioma. Cancer Epidemiol Biomarkers Prev\u20082004;13:461\u20137.","DOI":"10.1158\/1055-9965.461.13.3"},{"key":"2022061105411834700_B39","doi-asserted-by":"crossref","unstructured":"Louis DN, Holland EC, Cairncross JG. Glioma classification: a molecular reappraisal. Am J Pathol\u20082001;159:779\u201386.","DOI":"10.1016\/S0002-9440(10)61750-6"},{"key":"2022061105411834700_B40","doi-asserted-by":"crossref","unstructured":"Ohgaki H, Kleihues P. Population-based studies on incidence, survival rates, and genetic alterations in astrocytic and oligodendroglial gliomas. J Neuropathol Exp Neurol\u20082005;64:479\u201389.","DOI":"10.1093\/jnen\/64.6.479"},{"key":"2022061105411834700_B41","doi-asserted-by":"crossref","unstructured":"Mendelsohn J, Baselga J. Epidermal growth factor receptor targeting in cancer. Semin Oncol\u20082006;33:369\u201385.","DOI":"10.1053\/j.seminoncol.2006.04.003"},{"key":"2022061105411834700_B42","doi-asserted-by":"crossref","unstructured":"Halatsch ME, Schmidt U, Behnke-Mursch J, Unterberg A, Wirtz CR. Epidermal growth factor receptor inhibition for the treatment of glioblastoma multiforme and other malignant brain tumours. Cancer Treat Rev\u20082006;32:74\u201389.","DOI":"10.1016\/j.ctrv.2006.01.003"}],"container-title":["Clinical Cancer Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/aacrjournals.org\/clincancerres\/article-pdf\/13\/9\/2621\/1973387\/2621.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/aacrjournals.org\/clincancerres\/article-pdf\/13\/9\/2621\/1973387\/2621.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,6,11]],"date-time":"2022-06-11T20:51:16Z","timestamp":1654980676000},"score":1,"resource":{"primary":{"URL":"https:\/\/aacrjournals.org\/clincancerres\/article\/13\/9\/2621\/195818\/Association-between-Functional-EGF-61-Polymorphism"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2007,5,1]]},"references-count":42,"journal-issue":{"issue":"9","published-online":{"date-parts":[[2007,5,1]]},"published-print":{"date-parts":[[2007,5,1]]}},"URL":"https:\/\/doi.org\/10.1158\/1078-0432.ccr-06-2606","relation":{},"ISSN":["1078-0432","1557-3265"],"issn-type":[{"value":"1078-0432","type":"print"},{"value":"1557-3265","type":"electronic"}],"subject":[],"published":{"date-parts":[[2007,5,1]]}}}